Polomar Health Services, Inc. (PMHS) stock analysis
Close on Oct 19, 2026Market cap $3.37MP/E –Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Weak3 of 30 checks passed
Polomar Health Services passes 3 of the 30 checks behind our score; 20 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 2/6
- Past performance
- 1/6
- Financial health
- 0/6
- Dividend
- 0/6
What stands out
Revenue growing 10%+ a year
Revenue grew 166% a year over the last three fiscal years.
Growing faster than the industry
Revenue grew 7689% over the last twelve months; the Drugs median is 8.0%.
Net margin above its 5-year average
Net margin was -298% over the last twelve months, against a 5-year average of -1465%.
What to watch
Return on equity under 15%
Return on equity was -258% over the last twelve months and averaged -376% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was -207%, below the 10% that usually covers the cost of capital.
Interest not well covered
Operating income covers interest expense -90.3 times; we look for at least 5.
Gross margin slipping
Gross margin was 61.1% over the last twelve months, against 61.3% a year earlier.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B against the industry
Needs positive book value.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth2/6
Revenue growing 10%+ a year
Revenue grew 166% a year over the last three fiscal years.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing faster than the industry
Revenue grew 7689% over the last twelve months; the Drugs median is 8.0%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin slipping
Gross margin was 61.1% over the last twelve months, against 61.3% a year earlier.
Past performance1/6
Return on equity under 15%
Return on equity was -258% over the last twelve months and averaged -376% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was -207%, below the 10% that usually covers the cost of capital.
Return on equity below the industry
Polomar Health Services's return on equity of -258% is below the Drugs median of -58.9%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin above its 5-year average
Net margin was -298% over the last twelve months, against a 5-year average of -1465%.
Net margin below the industry
Polomar Health Services's net margin of -298% is below the Drugs median of -53.0%.
Financial health0/6
Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt coverage
Needs operating cash flow.
Interest not well covered
Operating income covers interest expense -90.3 times; we look for at least 5.
Short-term liquidity
The balance sheet is not split into current and non-current items.
Bankruptcy risk (Altman Z)
Needs market value, working capital and retained earnings.
Dividend0/6
No dividend
Polomar Health Services has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Polomar Health Services. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/B at month end
- Drugs median 2.3
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Margins
Share of revenue, fiscal years 2021 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +1002.0% | +165.8% | – | – | |
| Gross profit | +1388.8% | +137.1% | – | – |
Returns and balance sheet
5 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2021 | FY2021 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -290.1% | |
| Return on assets | – | – | -206.9% | |
| Current ratio | – | – | 0.20 | |
| Interest coverage | – | – | -69.9× | |
| Inventory turnover | – | – | 2.3× | |
| Diluted shares | – | – | 28M |
Cash use needs five years of cash flow figures
Polomar Health Services does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -1650.8% | 0.13× | 1.40× | -290.1% |
| FY2024 | -2280.2% | 0.01× | 1.18× | -31.4% |
| FY2023 | -1405.2% | 0.23× | 2.59× | -826.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero-$10.70M
- Cash generatingOperating cash flow above zero-$396.00K
- Return on assets improvedROA up on the prior year-1252.4% → -107.5%
- Earnings backed by cashOperating cash flow above net income-$396.00K vs -$10.70M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.06 → 0.20
- No dilutionShare count did not rise28M → 28M
- Gross margin improvedGross margin up on the prior year52.53% → 70.98%
- More efficientAsset turnover rose0.55 → 0.07
See a number that looks wrong?